Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$5.38
▼ $0.15 (-2.7%)
Market data updated: 09/20 03:18 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$117.74M
Day Range
$5.20 - $5.59
52-Week Range
$3.35 - $17.94
Beta
—
Next Earnings
11.11.2026
Support
$4.54
Resistance
$8.12
AARD is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-52.3% (1Y)
Strengths: 6/22 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 43.1%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 12.6% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
46
Quality
No data available
Value
55
Momentum
39
Risk
40
Sentiment
80
Fundamental
46
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Aardvark Therapeutics** has centered on its **clinical progress and financial updates**, particularly around its lead drug, **ARD-101**, in **Prader-Willi syndrome (PWS)**. The company reported **Q2 2026 earnings**, noting plans to review **unblinded Phase 3 HERO and open-label extension (OLE) data** in Q3 to guide next steps, including discussions with the **FDA** to resolve a **clinical hold**. Despite **ongoing losses**, the stock saw a **sharp after-market gain (8.5%)** in late August, while analysts maintained a **neutral outlook** with a **$6 price target**. Leadership continuity was confirmed, but no major strategic shifts were highlighted.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Aardvark Therapeutics, Inc.. News trend score: 80. Reason: 5 of the last 10 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
16
🎯 Conviction (vs. Emotion)
50
Psychology
17
Fundamentals
46
Technical
39
Valuation
55
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+37%
Market Narrative
46
Fundamental Reality
50
Narrative Gap
-4
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests **herding** dominates as traders align with peers’ underperformance, evidenced by AARD’s slight outperformance in a declining sector. The narrative-reality gap (-8) hints at a disconnect between positive sentiment (74) and technical weakness, potentially fueling cautious following rather than independent action. Anchoring (4.3% from support) may subtly reinforce hesitation, while the absence of panic or euphoria signals stability in risk-taking. The key question: *Will traders double down on sector alignment or exit if momentum worsens?*
Updated: 09/09/2026, 03:06 AM
What could change this?
👥 What the crowd believes
"Remains in active discussions with the FDA to support resolution of the clinical hold for ARD-101 program"
"Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026"
"HC Wainwright & Co. reiterates Aardvark Therapeutics with a Neutral and announces $6 price target"
"reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91)"
📈 18D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with some legendary investors seeing it as a rare opportunity while others dismiss it outright. Benjamin Graham’s *Defensive Investor* and *Enterprising Investor* models both rate it highly—one calling it ‘attractive’ due to its fundamentals, the other flagging a ‘statistical discount’—suggesting Graham would view it as a bargain with strong defensive traits. Meanwhile, Peter Lynch and Walter Bagehot’s near-perfect scores imply liquidity and potential, though Lynch’s hesitation stems from insufficient growth data, while Bagehot’s confidence hinges on resilience in a credit crunch. On the opposite end, Fisher, Housel, and Livermore reject it entirely—Fisher lacks fundamentals, Housel warns of volatility that could deter patient investors, and Livermore’s ‘negative trend’ verdict aligns with his strict trend-following rules. The middle ground is muddled, with Marks (both cycle and general) and Veblen expressing caution about inflated expectations or unclear profitability, while Loeb and the efficient-market camp flag high risk or argue passive investing is the safer play.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 100
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 82
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 82
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 80
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 65
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 57
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 55
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 53
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 34
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 13
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 5 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-54.0%
ROA
-49.1%
ROIC
—
EPS
-$2.93
Cash
$47.05M
Total Debt
—
Current Ratio
10.61
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$5.38
Estimated Fair Value (DCF)
-$51.59
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-59.69M | $-54.76M |
| 2 | 8.1% | $-64.54M | $-54.33M |
| 3 | 6.3% | $-68.58M | $-52.95M |
| 4 | 4.4% | $-71.58M | $-50.71M |
| 5 | 2.5% | $-73.37M | $-47.68M |
Base FCF (last actual year)
$-54.27M
Terminal Value
$-1.16B
Present Value of Terminal Value
$-751.94M
Enterprise Value
$-1.01B
Net Debt
$0
Equity Value
$-1.01B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$5.43
Tangible Book Value per Share (Tangible NAV)
$5.43
Sentiment based on basic keywords (not AI) — 5 positive, 5 neutral, 0 negative out of the last 10 articles.
Benzinga · 14.9.2026
Benzinga · 28.8.2026
Yahoo · 17.8.2026
GuruFocus.com · 17.8.2026
Yahoo · 11.8.2026
GlobeNewswire · 11.8.2026
Benzinga · 11.8.2026
Benzinga · 20.7.2026
ChartMill · 13.7.2026
Simply Wall St. · 28.5.2026
Aardvark Therapeutics, Inc. (AARD) currently has a StockIQ AI score of 49/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AARD currently scores 49/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
AARD's technical score is 39/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 43.1%; Current ratio: 10.61; +34.9% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: ATR: 12.6% of price; Calmar: -0.57 (3y annualized return -45.9% / max drawdown 80.0%); Return on equity (ROE): -54.0% (negative).
StockIQ has no recorded dividend payment history for AARD.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 7 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Tong Victor Edward Jr | Grant/Award from Employer | 14.8.2026 | 44,964 | +44,964 | — |
| Chi Jeffrey | Grant/Award from Employer | 14.8.2026 | 44,964 | +44,964 | — |
| Graf Susan E | Grant/Award from Employer | 14.8.2026 | 44,964 | +44,964 | — |
| Baynes Roy D. | Grant/Award from Employer | 14.8.2026 | 44,964 | +44,964 | — |
| Lee Tien-Li | Grant/Award from Employer | 9.2.2026 | 203,851 | -203,851 | — |
| Jaiman Manasi | Grant/Award from Employer | 9.2.2026 | 70,549 | -70,549 | — |
| Sun Nelson | Grant/Award from Employer | 9.2.2026 | 70,549 | -70,549 | — |
| Jaiman Manasi | Grant/Award from Employer | 9.2.2026 | 70,549 | -70,549 | — |
| Lee Tien-Li | Grant/Award from Employer | 9.2.2026 | 203,851 | -203,851 | — |
| Sun Nelson | Grant/Award from Employer | 9.2.2026 | 70,549 | -70,549 | — |
| Lee Tien-Li | Open Market Purchase | 11.12.2025 | 7,000 | +7,000 | $14.49 |
| Sun Nelson | Open Market Purchase | 11.12.2025 | 3,000 | +3,000 | $14.40 |
| Lee Tien-Li | Open Market Purchase | 11.12.2025 | 1,551,613 | +7,000 | $14.49 |
| Sun Nelson | Open Market Purchase | 11.12.2025 | 108,484 | +3,000 | $14.40 |
| Jones Bryan | Exercise of Derivative Securities | 15.10.2025 | 1,250 | -1,250 | — |
| Jones Bryan | Exercise of Derivative Securities | 15.10.2025 | 1,250 | +1,250 | $4.24 |
| Lee Tien-Li | Exercise of Derivative Securities | 15.10.2025 | 1,229 | -1,229 | — |
| Lee Tien-Li | Exercise of Derivative Securities | 15.10.2025 | 1,229 | +1,229 | $4.24 |
| Jones Bryan | Exercise of Derivative Securities | 15.10.2025 | 1,250 | +1,250 | $4.24 |
| Jones Bryan | Exercise of Derivative Securities | 15.10.2025 | 40,052 | -1,250 | — |
| Lee Tien-Li | Exercise of Derivative Securities | 15.10.2025 | 1,544,613 | +1,229 | $4.24 |
| Lee Tien-Li | Exercise of Derivative Securities | 15.10.2025 | 40,566 | -1,229 | — |
| Lee Tien-Li | Open Market Purchase | 15.9.2025 | 3,500 | +3,500 | $9.94 |
| Lee Tien-Li | Open Market Purchase | 15.9.2025 | 6,500 | +6,500 | $9.51 |
| Lee Tien-Li | Open Market Purchase | 15.9.2025 | 1,539,884 | +6,500 | $9.51 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
509,891 shares short as of 2026-08-31 · vs. 652,496 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
50.8% of trading volume this week was short selling, vs. 29.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology